Silence Therapeutics (NASDAQ:SLN) Stock Price Up 4%

Shares of Silence Therapeutics plc (NASDAQ:SLN) rose 4% on Monday . The company traded as high as $19.65 and last traded at $19.65. Approximately 1,378 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 195,118 shares. The stock had previously closed at $18.90.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SLN. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Thursday, June 20th. Chardan Capital restated a “buy” rating and set a $42.00 target price on shares of Silence Therapeutics in a research report on Friday, May 17th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $45.00 price target on shares of Silence Therapeutics in a research report on Monday, April 22nd.

Silence Therapeutics Stock Performance

The stock has a 50 day moving average of $21.35 and a 200-day moving average of $20.95.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.18. The firm had revenue of $15.73 million during the quarter, compared to analysts’ expectations of $4.53 million. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. On average, research analysts predict that Silence Therapeutics plc will post -1.52 earnings per share for the current year.

Institutional Investors Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Redmile Group LLC purchased a new stake in shares of Silence Therapeutics during the first quarter worth about $43,798,000. Vivo Capital LLC boosted its position in shares of Silence Therapeutics by 116.7% during the first quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock worth $23,878,000 after acquiring an additional 595,250 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Silence Therapeutics during the first quarter valued at $13,575,000. Lynx1 Capital Management LP increased its holdings in Silence Therapeutics by 123.4% in the 1st quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after acquiring an additional 290,855 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares in the last quarter. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.